Larimar Therapeutics (NASDAQ:LRMR) is a biotechnology company dedicated to the development of innovative therapies for complex rare diseases. Using their unique protein replacement therapy platform, they are focused on advancing treatments that target the fundamental causes of these conditions. Their leading project, CTI-1601, is in clinical trials, aiming to treat Friedreich's ataxia, a debilitating, life-shortening neuromuscular disorder. Larimar's objective is to pioneer first-of-their-kind therapeutics to address unmet medical needs, ultimately improving the quality of life for patients with rare diseases. The company is committed to rigorous scientific research, strategic collaborations, and the pursuit of excellence in everything they do to bring groundbreaking therapies from the lab to the patients who need them most.